This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hatzoglou, A. Articles by Castanas, E. Search for Related Content PubMed PubMed Citation Articles by Hatzoglou, A. Articles by Castanas, E. Related Collections Male Endocrinology

Membrane Androgen Receptor Activation Induces Apoptotic Regression of Human Prostate Cancer Cells in Vitro and in Vivo

Departments of Experimental Endocrinology (A.H., M.K., C.K., E.C.), Pharmacology (I.C., A.G.), Biochemistry (P.A.T., E.A.P., C.S.), Urology (P.A.), and Pathology (C.D., E.N.S.), University of Crete School of Medicine, Heraklion GR-71110, Greece

Address all correspondence and requests for reprints to: Dr. Elias Castanas, Laboratory of Experimental Endocrinology, University of Crete School of Medicine, P.O. Box 2208, Heraklion GR-71003, Greece. E-mail: castanas{at}med.uoc.gr.

Nongenomic androgen actions imply mechanisms different from the classical intracellular androgen receptor (iAR) activation. We have recently reported the identification of a membrane androgen receptor (mAR) on LNCaP human prostate cancer cells, mediating testosterone signal transduction within minutes. In the present study we provide evidence that activation of mAR by nonpermeable, BSA-coupled testosterone results in 1) inhibition of LNCaP cell growth (with a 50% inhibitory concentration of 5.08 nM, similar to the affinity of testosterone for membrane sites); 2) induction in LNCaP cells of both apoptosis and the proapoptotic Fas protein; and 3) a significant decrease in migration, adhesion, and invasion of iAR-negative DU145 human prostate cancer cells. These actions persisted in the presence of antiandrogen flutamide or after decreasing the content of iAR in LNCaP cells by iAR antisense oligonucleotides. Testosterone-BSA was also effective in inducing apoptosis of DU145 human prostate cancer cells, negative for iAR, but expressing mAR sites. In LNCaP cell-inoculated nude mice, treatment with testosterone-BSA (4.8 mg/kg body weight) for 1 month resulted in a 60% reduction of tumor size compared with that in control animals receiving only BSA, an effect that was not affected by the antiandrogen flutamide. Our findings suggest that activators of mAR may represent a new class of antitumoral agents of prostate cancer.

This article has been cited by other articles:

				V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF]

				C.-S. Yang, H.-W. Xin, J. B. Kelley, A. Spencer, D. L. Brautigan, and B. M. Paschal Ligand Binding to the Androgen Receptor Induces Conformational Changes That Regulate Phosphatase Interactions Mol. Cell. Biol., May 1, 2007; 27(9): 3390 - 3404. [Abstract] [Full Text] [PDF]

				J. W. Gatson and M. Singh Activation of a Membrane-Associated Androgen Receptor Promotes Cell Death in Primary Cortical Astrocytes Endocrinology, May 1, 2007; 148(5): 2458 - 2464. [Abstract] [Full Text] [PDF]

				L. Bonaccorsi, D. Nosi, M. Muratori, L. Formigli, G. Forti, and E. Baldi Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines J. Mol. Endocrinol., January 1, 2007; 38(1): 51 - 66. [Abstract] [Full Text] [PDF]

				M. Kampa, C. Kogia, P. A. Theodoropoulos, P. Anezinis, I. Charalampopoulos, E. A. Papakonstanti, E. N. Stathopoulos, A. Hatzoglou, C. Stournaras, A. Gravanis, et al. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1342 - 1351. [Abstract] [Full Text] [PDF]